Mdm2, a negative regulator of the tumor suppressor protein P53, can suppress its functions. Mdm2 antagonists, like Nutlin-3 and RG7112, interfere with the Mdm2-P53 interaction. By doing so, they free P53 to exert its anti-cancer activities, including cell cycle arrest and apoptosis. This makes Mdm2 antagonists a promising avenue for cancer treatment, unleashing the power of the body's natural defense mechanisms against cancer cells.